Pharmacokinetic and pharmacodynamic research is regularly reported in most contemporary anaesthesia-oriented journals. This sub-specialty area of pharmacology grew rapidly from the 1960s as various essential concepts and tools-laboratory analysis of drug/metabolite concentrations in biofluids, physiological signal collection, and methods for analysing/presenting relevant pharmacokinetic and pharmacodynamic data-started coming together. For Australia, such research began in Sydney in the mid-1960s with collaboration between anaesthetist Dr C.R. Climie (1923Climie ( -2013 at the Royal Hospital for Women and medicinal chemist Dr J. Thomas OAM (1928-2017, and was achieved through a succession of postgraduate research student projects in the Department of Pharmacy of The University of Sydney, initially supervised by Dr Thomas. These consisted of studies concerned with the systemic absorption and placental transmission of drugs being used in parturients. By the late 1960s, Sydney anaesthetists Drs G.J. Long and C.A. Shanks (1936Shanks ( -1998 were also participating, and the projects were becoming more complex, including studies of the metabolism of local anaesthetics and other drugs by mothers and neonates. Between the mid-1970s and early-1980s, with additional anaesthetists, postgraduate research students and their academic supervisors participating, the projects focussed mainly on the pharmacokinetics and pharmacodynamics of neuromuscular blocking agents. This form of chemical-clinical-pharmacologically-based anaesthesia-oriented research that started in Sydney with the collaboration of Drs Climie and Thomas led to many challenging higher degree projects for pharmaceutical scientists, and access to unprecedented research capabilities for anaesthetists. Most significantly, it established a permanent place for multidisciplinary pharmacokinetic-and pharmacodynamic-based research within Australian academic departments of anaesthesia.
In his obituary on Dr Colin Richmond ('Dick') Climie MBChB FFARCS FFARACS (1923 -2013 , Dr Eddie Loong observed that "…In spite of an onerous workload, understaffing and negligible funding for research, he oversaw and engaged in a wide variety of original research projects and their associated publications…." 1 . Altogether, Dr Climie was the author or co-author of around a dozen 'associated publications', with about half coming from procedural issues associated with obstetric anaesthesia, and the remainder from collaborative research performed in the course of his practice as Senior Staff Specialist at Sydney's Royal Hospital for Women and conjoint Lecturer in the Department of Surgery at the University of NSW 2 in Sydney between 1963 and 1984. These publications were at the forefront of a new direction in chemical laboratory-based anaesthesia-oriented research in Australia.
The purpose of this essay is to outline the genesis of the chemical laboratory-based anaesthesia-oriented research that began in Sydney in 1965 with collaboration between Dr Climie (see Figure 1 ) and Dr John (Jack) Thomas OAM MSc PhD FPS (1928 -2017 . Dr Thomas (see Figure 2) , who had originally trained as a pharmacist in the UK in the 1950s, was then Senior Lecturer (later Associate Professor) in Medicinal Chemistry in the Department of Pharmacy at The University of Sydney 3 . Their initial collaboration started with a study of local anaesthetic-induced methaemoglobinaemia and soon progressed to research studies examining the systemic absorption and placental transmission of drugs used in obstetric anaesthesia. The patient management part was performed by Dr Climie as the responsible anaesthetist, and the laboratory part was performed by a postgraduate scientist being supervised by Dr Thomas as part of a higher degree candidacy, normally MSc or PhD, in the Department of Pharmacy of The University of Sydney. In each case, the postgraduate scientist was responsible for establishing, as appropriate, experimental design, quantitative and/ or qualitative methodology for drug/metabolite analysis, statistical treatment and presentation of data, and finally, the preparation of a thesis based on the studies. Apart from the obvious role of mentorship, the supervisor was also responsible for provision of the laboratory facilities necessary for the dependent studies to proceed. This then established the collaborative pattern for all ensuing studies.
In 1967, this multidisciplinary form of research with Dr Thomas began involving additional Sydney anaesthetists, notably Drs Geoffrey J. Long MBBS FFARCS FFARACS, and Colin A. Shanks MBChB FFARCS FFARACS (1936-1998) , both being staff specialists at the Royal Prince Alfred Hospital and conjoint tutors in anaesthetics at the University of Sydney 4 . From the mid-1970s, the collaborative projects began to involve greater numbers of anaesthetists, postgraduate research students and their academic supervisors, and the research topics broadened to include more diverse and complex studies of the disposition in mothers and neonates of local anaesthetic agents used for obstetric anaesthesia, and of the pharmacokinetics and pharmacodynamics of neuromuscular blocking agents in patients and in laboratory animals. Table 1 gives an overview of the personnel and research topics of the period from 1967, the year of Dr Climie's first collaborative research publication, to 1984, by which time the principal senior personnel had either retired or had other commitments. A list of relevant research publications of Drs Climie, Long, Shanks and Thomas is given in Appendix 1.
In this essay, references to the work of others represent predominant and formative opinions, concepts and tools related to this research, but are by no means exhaustive. Additionally, the term 'chemical-clinical pharmacology' is used to indicate emphasis on the chemical laboratory investigation of clinically-indicated drugs and their metabolites, principally through their measurement in biofluids in the context of pharmaceutical sciences. This terminology is used to cautiously differentiate between 'pharmacology' and 'clinical pharmacology'-the former being the all-inclusive study of drug actions, and the latter then being an emerging subdiscipline of medicine oriented towards therapeutics, and sometimes involving the monitoring of their biofluid concentrations. This period in the mid-1960s became the genesis of an Australia-wide multidisciplinary pattern as part of a global movement, supporting research in both anaesthesia and pharmacological sciences, producing challenging clinicallyoriented postgraduate research projects for pharmacological scientists, and offering unprecedented laboratory research capabilities for anaesthetists. This essay is written from the perspective of one of the scientists of that period whose postgraduate research degree candidacies were supervised by Dr Thomas and who worked collaboratively with Drs Climie, Long and Shanks. Climie MB ChB FFARCS FFARACS (1923 -2013 . Image courtesy of the Climie family.
Figure 2: Dr John (Jack) Thomas OAM MSc PhD FPS (1928 -2017 . Image courtesy of Megan Haggan, Australian Pharmaceutical Publishing Company.
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The beginning
In their account of the historical developments of labour analgesia in Australia, Dr Eley and colleagues 5 record that "Dr Richard Climie…promoted the use of regional analgesia and anaesthesia and supported research within his department. He co-authored several papers concerning the maternal and neonatal serum levels of local anaesthetics", citing two such papers published in 1969.
Before the initial collaboration of Drs Climie and Thomas, a similar research model had already been established in the 1950s between the renowned anaesthesiologist Dr E. (Manny) Papper (1915 Papper ( -2002 and prototypic chemical pharmacologist Dr Bernard B. (Steve) Brodie (1907 Brodie ( -1989 at Columbia University, New York. Apart from the willingness of the personnel to collaborate on an issue, the effectiveness of such collaborations requires individual participants to contribute their expertise and facility with specific and relevant methodological concepts and experimental tools. The Columbia collaboration had all of these elements, producing amongst others, landmark research studies of pethidine 6, 7 and thiopentone [8] [9] [10] . In the early 1960s, as judged by mainstream journals, anaesthesia-oriented clinical research was largely concerned with patient management techniques and outcomes, and anaesthesia-oriented pharmacological research was more animal laboratory-based than clinical. Concurrently, and largely as a result of advocacy by distinguished North American academic anaesthetists, most notably Drs John J. Bonica (1917 Bonica ( -1994 11 and Daniel C. Moore (1918 Moore ( -2015 12 both in Seattle, and Dr Philip R. Bromage (1920 Bromage ( -2013 in Montreal, regional anaesthesia for perioperative pain management and parturition was in resurgence 14 . These opinions influenced many anaesthetists, including Dr Climie in Sydney. This period also coincided with the transition from the older amino ester-type (procaine-like) local anaesthetic agents that were hydrolysed in the blood, to the newer amino amide-type (lignocaine-like) local anaesthetic agents that were metabolised in the liver. Research into the biological fate of lignocaine had been the subject of interest from the time of its introduction in the early 1950s, but such work generally remained in the scientific, rather than medical domain 15 . However, with the increasing clinical use of lignocaine, anaesthetists were needing to be reassured that its doses would be unlikely to produce systemic toxicity 16 . Prilocaine was introduced in the early 1960s as a relatively safe (amino amide-type) local anaesthetic agent on the basis of laboratory studies indicating its intrinsic central nervous system toxicity to be somewhat less than lignocaine 17 . Also around this time, Australian-born Edinburgh academic anaesthetist Dr David B. (Bruce) Scott (1925 Scott ( -1998 and his colleagues performed the first systematic studies of the resultant blood concentrations of lignocaine and prilocaine when used for neural blockade. They analysed the main factors affecting the plasma drug concentrations in terms of the particular agent employed, its dose, its site of injection, the use of a vasoconstrictor, along with evaluation of related factors affecting their risks of causing systemic toxicity 18, 19 . This work was augmented by that of Bromage who further examined the relationships between other patient variables, such as age, and dose requirements for epidural anesthesia with these agents 20 .
With the increasing use of regional anaesthesia for labour and delivery, there was an additional need to understand the placental transmission of the agents used. A few years earlier, attention had been drawn to the clinical significance of the placental transmission of maternally administered drugs through the tragedy of thalidomide that had been introduced as a mild sedative for pregnant women with morning sickness. By 1960 in Germany, a rare birth defectphocomelia, was being observed far more frequently than ever. In 1961, Sydney obstetrician Dr William G. (Bill) McBride delivered three babies with phocomelia and he realised that the only common factor was that their mothers had taken thalidomide during early pregnancy 21 . Dr McBride, among others, contacted the manufacturers, Chemie Grünenthal, a small pharmaceutical company in the former West Germany, with his suspicions that thalidomide might be the cause of these birth defects. This was accepted, and thalidomide was withdrawn by the end of 1961.
Following thalidomide, the use of drugs in obstetric patients, including those used by anaesthetists during labour and delivery, began to receive greater attention. Prominent academic anaesthetists drew attention to this issue in both the mainstream clinical 22 and pharmacological literature 23 . Notably, British obstetric anaesthetist Dr J. Selwyn (Jeff) Crawford (1922 Crawford ( -1988 24 was one of the first to perform chemical laboratory measurements of the concentrations of commonly-used drugs in maternal and cord blood 25, 26 . He found that slowing the rate of drug introduction into the mother could decrease the extent of placental transmission by effectively diluting the concentration of drug in a greater volume of the mother's blood 27, 28 , a notion that influenced Climie's methods.
In 1965, prilocaine was introduced into the labour ward at the Royal Hospital for Women in Sydney. Climie observed "brown blood" in some patients who had received epidural anaesthesia with prilocaine. He discussed this with Dr Thomas who was then supervising the research projects of two PhD candidates, pharmacist Stuart McLean and pharmacologist Graham Starmer (1932-2016) , on methaemoglobinaemia caused by aromatic amine-and amide-type substances and their metabolites that were chemically related to the analgesic drug phenacetin. Prilocaine was also metabolised to substances chemically similar to phenacetin metabolites, and so they also investigated the formation of methaemoglobin in the mothers and neonates where prilocaine had been used for obstetric epidural anaesthesia. They found that if the dose of prilocaine was sufficient, its metabolites could cause significant methaemoglobinaemia in the mother, and then it would be likely to also cause significant methaemoglobinaemia in the neonate. As shown in Table 1 and Appendix 1, this original research question led directly to many others, with the analogous collaborative participation of many other Australian anaesthetists, medical specialists, and scientists.
The essential ingredients
In the mid-1960s, the essential 'chemical-clinical pharmacology' concepts and tools were not yet generally found in academic departments of anaesthesia, or even of pharmacology. However, they were beginning to accrue in the many academic departments of pharmacy that were emerging from traditional materia medica research and apprenticeship-based education formats into modern science-based formats.
Both Climie and Thomas took up their respective positions in Sydney in 1963, the same year that Professor Douglas Joseph (Table 1) . Analogous collaborative projects, based upon similar chemical-clinical pharmacological patterns, also occurred with postgraduate research students from the Department of Pharmacy and their supervisors collaborating with medical specialists in other academic medical departments, including cardiology, psychiatry, gerontology, neurology and rheumatology. Again, a detailed discussion of these collaborations is beyond the scope of this essay.
Moreover, from the mid-1970s, the anaesthesiapharmacological science movement spread to other Australian cities, especially as graduates of the original collaborations took positions elsewhere. In this regard, the establishment of a new Department of Anaesthesia and Intensive Care at Flinders Medical Centre in Adelaide provided from its inception integrated and multidisciplinary clinical and chemical pharmacological research capabilities. Through the 1980s, further research collaborations formed in Sydney between anaesthetists at Prince Henry Hospital with the Department of Clinical Pharmacology at St Vincent's Hospital/University of NSW, and analogous collaborations were established in Melbourne, Brisbane and Perth. All would contribute to significant advances in applied knowledge, as well as in the essential pharmacological concepts and tools that underpin the broader discipline of anaesthesiology.
The concepts and tools
The pioneering work of Papper and Brodie was based on measurements of drug concentrations in plasma, thereby providing a much more precise method of linking to drug action than through drug dose, particularly during anaesthesia and surgery when homeostasis is inevitably disturbed 30 . The term 'pharmacokinetics' was coined in the 1950s, and its purpose is to determine the effect of a body on a drug, i.e., how a dose of a drug, once administered, becomes affected by body processes over time. The associated term 'pharmacodynamics' is often used rather loosely but it really means what the drug does to the body in a quantitative sense. Anaesthetists have long known that control of the concentrations of an inspired anaesthetic agent provides control over the time course and depth of anaesthesia 31 , and that there is a logical 'pharmacokinetic'-'pharmacodynamic' link that underpins much of their pharmacological management of patients 32 . But even into the 1960s, the relationships between the various properties of the agents and their pharmacological effects as mediated by their blood concentrations, although well-known in concept, had not been actualised for most agents because of the inability to measure their circulating blood concentrations with sufficient specificity and/or sensitivity.
This essay is based on research in Sydney in the mid1960s, but most of the essential concepts and tools were developing elsewhere. Some primary examples include the following. At the School of Pharmacy, University of London, Professor Arnold H. (Joe) Beckett (1920 Beckett ( -2010 , notable for his prescient proposal of an 'opioid receptor' on the basis of the stereochemistry of molecules affecting their analgesic activity 33 , was supervising a cohort of postgraduate research students who were developing the chemical analysis of analogous drugs with gas-liquid chromatography (GLC), initially for sports 'doping' testing procedures 34 . At the School of Pharmacy, University of California, San Francisco, Drs Sidney Riegelman (1921 Riegelman ( -1981 and Les Benet were creating research concepts regarding rates and extents of drug absorption and distribution [35] [36] [37] [38] . At the State University of New York in Buffalo, Drs Gerhard (Gary) Levy (1928 -2017 ) and Milo Gibaldi (1938 -2006 were developing compartmental methods of analysis of drug behaviour in the body, allowing summary data to be created from the time course of serial measurements 39 . At the University of Michigan, Dr John G. Wagner (1921 Wagner ( -1998 was performing both theoretical and practical research into the fundamental role of pharmacokinetics and pharmacodynamics with all modes of drug treatment [40] [41] [42] . All of these essential concepts and tools would, in one way or another, be incorporated into most of the projects.
The technique of GLC had evolved during the late 1950s, and was a valuable means of 'fingerprinting' the proportional composition of a complex organic mixture such as an essential oil. When this author commenced his postgraduate research in 1966, GLC was rapidly becoming especially useful as a quantitative tool, because it permitted a substantial improvement in specificity and sensitivity over the century-old spectroscopic methods used in prior anaesthesia-pharmacology research. Moreover, some of the relevant anaesthesia-pharmacology research was starting to be based on GLC methodology [43] [44] [45] . Its specificity meant that GLC was capable of differentiating between chemically similar substances such as lignocaine, pethidine and promazine that were often being used concurrently in patients, whereas spectrometric methods could not. GLC rapidly became the world standard laboratory measurement tool for drugs (and/ or their metabolites) that could be made sufficiently volatile to pass into the gas phase. However, not all drugs could be assayed this way. Notably, neuromuscular blocking agents, being permanently charged non-volatile substances, could not be measured by GLC. For this author's first encounter with the then new neuromuscular blocking agent alcuronium in a project with Dr Climie in 1967, a pharmacological bioassay technique was used with a smoked drum recording apparatus that had not changed from the 19th century! However, by the late 1970s, measurement of the biofluid concentrations of these agents was based on newer and superior spectrofluorimetric methods. In the late 1970s, GLC became progressively supplemented by high performance liquid chromatography (HPLC) and this was readily adaptable to almost all drugs as it did not require substances to be volatile. A range of more sensitive and versatile detectors progressively became available: these included nitrogenselective detectors for GLC, diode array detectors for HPLC, and later, mass spectrometric (MS) detectors for both. These GLC-MS and HPLC-MS techniques subsequently became mainstay tools for identification of substances, such as metabolites of the subject drugs.
In some projects, the initial anaesthesia-based research required additional collaboration between the pharmacological scientists and highly specialised chemists who were the overseers of the necessary and very expensive instrumentation, such as the high-resolution mass spectrometers required to determine the structure of metabolites of the subject drugs. The resultant publications became substantial works of advanced analytical and organic chemistry, and these normally did not involve the anaesthetist collaborators.
The evolutionary developments in chemical analysis technologies thereby allowed the pharmacokinetics of almost any drug substance to be studied, both practically and conceptually. When aided by developments in mathematical and computational methodology, pharmacokinetics developed rapidly during the 1970s and thereby became a versatile tool and concept 46 . In what has now become traditional (compartmental and non-compartmental) pharmacokinetics, the serial drug concentration data are usually reduced to summary data that can be used to compare values for the variables, such as extent of distribution or rate of clearance, between individuals, or between drugs, or to examine the effects of another variable, such as age or an imposed condition or pathophysiology, on a particular drug substance 47 . Additionally, such data are useful to be able to predict and compare, say the consequence of multiple doses, or alternative modes of administration 48 . But such pharmacokinetic effort is somewhat hollow without linkage to information about drug effects. Accordingly, much effort was invested in clinical laboratories for describing a drug's 'therapeutic window', that is, the drug blood concentration below which 'therapeutic effects' were unlikely and above which 'toxic effects' were likely, and algorithms for drug dosing regimens were built around this concept, for example, for the prescribing of gentamicin. These essential concepts thus became the starting point for more advanced studies, for example with neuromuscular blocking agents used in surgical patients.
The collaborative research
As indicated above, the earliest collaborative research included relatively simple, but nevertheless exacting, studies such as prilocaine-induced methaemoglobinaemia, and the blood concentrations resulting from the systemic absorption of lignocaine used epidurally and topically for analgesia in parturients, along with its placental transmission as measured by its concentrations in cord blood, and the effects of added adrenaline thereon. When bupivacaine became available, it too was studied, and its first investigations in Australia by Climie and Long included studies of its systemic absorption and placental transmission after epidural administration in parturients, as well as its disposition and systemic effects after intravenous administration in healthy volunteer subjects. Observation of differences in the extent of placental transmission between different local anaesthetic agents led to explanatory measures such as the differential extents of the agent's plasma protein binding in maternal and foetal blood being determinants of its degree of placental transmission, a topic that, as it turned out, was being studied concurrently in Seattle 49, 50 and London 51, 52 . Other studies of that period involved examination of the metabolism and excretion of local anaesthetic agents by both mother and neonate, and to include new anaesthetist collaborators. Studies of the then new etidocaine and other older sedative and analgesic drugs, including chlormethiazole and diazepam, followed, mainly with Foundation 41 at the Crown St Women's Hospital, the Royal North Shore Hospital, and the National Women's Hospital, Auckland, New Zealand, again with additional anaesthetist and pharmacological science research collaborators.
Modelling concepts proposed concurrently in the 1970s by pharmacometrician Dr Lewis Sheiner (1940 Sheiner ( -2004 , meant pharmacodynamics came to mean the quantitative response or effect of a drug in relation to its concentration in some relevant site. This could be in the blood or plasma, often the unbound concentration of the drug in blood or plasma, and sometimes the calculated concentrations in an 'effect compartment', the hypothetical site that contains the drug receptors causing the particular effect. The concept, first advanced for neuromuscular blockade from muscle relaxants where a graded response could be measured readily on a continuous scale from nil to complete, was computationally developed further with additional physiological measures, and applied to intravenous anaesthesia 55, 56 . As chemicalanalytical methodologies improved, subsequent studies by Shanks and collaborating colleagues concentrated on neuromuscular blocking agents, with sophisticated clinical and laboratory methodology used in humans and dogs, thereby leading to pharmacokinetic-pharmacodynamic modelling to explain and compare the behaviour of various agents of the same drug class, as well as to determine the impact of hepatic or renal pathology on the outcomes. These projects were supervised mainly by Dr (later Professor) E.J. (Ted) Triggs (1942 Triggs ( -2007 , a specialist in pharmacokinetics, and Dr (later Professor) Ken Brown, a specialist in pharmaceutics ( Table 1 ).
The end of the beginning
As Drs Climie, Long and Thomas tapered their collaborative research in the 1970s, Dr Shanks became the predominant Sydney academic anaesthesia researcher with several scientist collaborators-albeit, as recorded by Professor Baker, under somewhat constrained circumstances 57 . In 1982, Dr Long retired from clinical anaesthesia, and Dr Shanks departed Sydney to continue his research in a largely research-oriented academic position at Northwestern University in Chicago where clinical-scientific research collaborators and collaborations were already established 58 . In the 1990s, Professor Baker and Professor Peter Kam would become the major collaborative researchers with (then) Associate Professor Ramzan holding joint appointments in the University of Sydney Departments of Pharmacy and Anaesthesia as an indication of his long-standing contributions to both disciplines. In January 2000, Dr Thomas was awarded the Medal of the Order of Australia, quite appropriately, "for service to the pharmacy profession, particularly through the continuing education of practising pharmacists". Surprisingly, however, there was no mention of his prolific research contributions.
Many other departments of anaesthesia elsewhere in Australia also, of course, took up similar collaborative research. It is significant to note the contributions of Dr (later Professor) Michael Cousins to the 1970s Sydney collaborative research works of those formative years, no doubt a useful prelude to the long period of collaboration later undertaken together with this author, both at Flinders Medical Centre in Adelaide and again at the University of Sydney and Royal North Shore Hospital.
Dick Climie, Jack Thomas, and bupivacaine
In early 1968, I had commenced working as a PhD candidate under the supervision of Dr Thomas. Dr Climie, who had read about bupivacaine, then a very new longacting local anaesthetic and still often referred to by its development designation as LAC-43, ordered some from the UK for trialling in patients and for our collaborative research on its systemic absorption and placental transmission. Upon notification of its arrival, I went to the Customs office of at Sydney's Kingsford-Smith Airport to collect the box containing 100 ampoules of 0.5% bupivacaine HCl (Marcaine®) that Dr Climie had ordered. The Customs Officer refused to release the box to me, saying that it was not on his list of 'permitted' drugs, and that he had never heard of that particular agent, anyway. He then referred to the current Prescription Proprietaries Guide and asked me to show him the entry for this new local anaesthetic, bupivacaine-which, of course, was not there! He went on "…How could he know that it wasn't a prohibited narcotic..., etc., etc.", and I went away empty-handed-all my explanations about our planned research and the fate of my thesis notwithstanding. It took many months for Dr Thomas to convince the Minister responsible for Customs that it should be released, for Dr Climie to become the first anaesthetist in Australia to use it clinically and for my PhD research project to proceed. Despite its shaky start in Australia in 1968, bupivacaine was soon introduced into Australian anaesthesia, as elsewhere.
Conclusions
In this essay, the case is claimed that collaborative anaesthesia-oriented chemical-clinical-pharmacologicallybased research started in Sydney in 1965 with Dr Climie, Dr Thomas, and studies of regional anaesthesia for obstetric patients. With additional participating anaesthetists and a succession of postgraduate student projects, this pattern matured, and subsequently spread beyond Sydney as various graduates of the original collaborations took positions elsewhere, and analogous collaborations formed. As a result, the supporting concepts and tools developed rapidly. This collaborative pattern offered anaesthetists unprecedented experimental laboratory techniques, and anaesthetists not infrequently became exposed to different interpretations of their clinical precepts. It offered scientists the opportunity to become exposed to 'real world' pharmacology, often under less-than-ideal experimental conditions where the needs of the patient came first. Some of those scientists went on to long-term academic associations with the discipline of anaesthesia, others went to senior academic positions in cognate disciplines, and yet others went to positions of influence in the pharmaceutical industry. This, also then, is the nature of collaborations-where specialists of one kind or another have to justify their models and interpretations of the same observations to others who have different models-and everyone then benefits greatly.
